15-Lipoxygenase-1 Is Involved in the Effects of Atorvastatin on Endothelial Dysfunction

Figure 3

Changes in expression levels of ALOX15, AKT, eNOS, VCAM-1, and ICAM-1 in HUVECs 24 h following exposure to ox-LDL (100 mg/L) or atorvastatin (10 μM). (a) Photographs of Lv-GFP-transfected HUVECs. GFP expression was visualized by fluorescence microscopy (100x) at 24, 48, and 72 h after transfection. The scale bar represents 10 μm. (b) and (c) Western blot and EIAs indicated that Lv-shALOX15 downregulated ALOX15 protein expression and enzyme activity. (d) and (e) Western blot and EIAs indicated that Lv-ALOX15 upregulated ALOX15 protein expression and enzyme activity. (f) Western blot analysis of AKT/eNOS expression in HUVECs. (g) Western blot analysis of VCAM-1/ICAM-1 expression in HUVECs. Group 1: normal control group; Group 2: ox-LDL (100 mg/L); Group 3: ox-LDL (100 mg/L) + atorvastatin (10 μM); Group 4: Lv-GFP + ox-LDL (100 mg/L) + atorvastatin (10 μM); Group 5: Lv-shALOX15 + ox-LDL (100 mg/L) + atorvastatin (10 μM); and Group 6: Lv-shALOX15 + ox-LDL (100 mg/L) + atorvastatin (10 μM). Results are expressed as mean ± SD. NC: normal control group; NS: not significant. , , and versus Group 1; and versus Group 2; and , , and versus Group 4. per group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)